



Small but heading for the big time

Nanobiotix 2014 Q4 and annual revenues

Paris, France, 27 February, 2015 – NANObIOTIX (Euronext: NANO – ISIN: FR0011341205) – a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenues for Q4 and the annual revenues for the year ended December 31, 2014.

Revenues at December 31, 2014

<i>In €</i>	<i>12/31/2014 (12 months)</i>	<i>12/31/2013 (12 months)</i>
Revenue	972,908	190,068
of which:		
License	967,500	185,030
Services	5,408	5,038

Revenue for Q4 2014

<i>In €</i>	<i>Q4 2014</i>	<i>Q3 2014</i>	<i>Q2 2014</i>	<i>Q1 2014</i>
Revenue	832,337	46,631	48,596	45,343
of which:				
License	829,958	46,351	45,847	45,343
Services	2,379	280	2,749	-

Activity

Nanobiotix revenues for the fourth quarter of 2014 include the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract signed in August 2012. This covers the development and commercialization of NBTXR3 in the Asia-Pacific region. The upfront payment totaled €810,640, generating revenue of €46,351 over the period based on a straight-line method of apportioning the revenue across the period between the date the contract was signed and the scheduled marketing launch in the region.

The revenues for this period also include a milestone payment of \$1.0m (€783,607) received in October 2014 pursuant to the contract with PharmaEngine, reflecting the fact that PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific region. In accordance with the contract between Nanobiotix and PharmaEngine, Nanobiotix is eligible for development and commercialization milestone payments of up to \$56.0m plus tiered, up to double-digit royalties on all net product sales in the Asia-Pacific region.

The invoicing of services totaled €2,379 for the quarter. In total, revenue for Q4 amounts to €832,337, totaling €972,908 for the year.

In November 2014, Nanobiotix secured financing from US investor, Capital Ventures International, through a private placement to further strengthen the Company's financial position. CVI acquired 650,000 new shares with warrants attached for a total subscription amount of €10,393,500, (representing around 4.85% of the Company's outstanding shares prior to the private placement), which may be supplemented by an amount of up to € 14,059,500 in case of exercise of all the warrants. Subject to certain conditions, the investor has also committed to purchase an additional tranche of up to €10 million that the Company may issue in its discretion.

The foregoing transactions are described in more detail in the press releases published by the Company at the time of their completion.

The rationale for this private placement was to provide Nanobiotix with funding to assist in the development of NBTRXR3, its main product, including to i) enable the Company to expand the indications and the geographical area for its lead product NBTXR3 ii) provide the financial visibility to drive a standalone strategy in US until reconsidering partnering options and iii) structure capital through a new US based shareholder.

2014 - A successful year of clinical progresses

Following the positive Phase I clinical study results for NBTXR3, presented at ASCO in June 2014, Nanobiotix received approval from the French National Security Agency for Medicines and Health Products (ANSM) to start a Phase II/III pivotal trial in soft tissue sarcoma (STS). This is the final step before registration (CE mark).

The Company expanded its clinical development program with new high potential indications in the US and Europe: liver cancers (primary and metastatic) and prostate cancer, in parallel with STS and head & neck trials already underway in Europe.

Click on the following link to download the 2014 review

[Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar | nanobiotix](#)

Next financial press release: revenue for the full year results of 2014 by 30 April, 2015

-Ends-

Notes to Editors

About NANOBIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of cancers including Soft Tissue Sarcoma, Head and Neck Cancer, Liver Cancers, Prostate Cancer, Breast Cancer, Glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for Soft Tissue Sarcoma and locally advanced Head and Neck Cancer. The company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). The company, based in Paris, France, opened an affiliate office in the Boston area of the US in September 2014.

Contact

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com



Media relations

France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - Instinctif Partners
Melanie Toyne Sewell / Ruth Ashton
+44 (0) 207 457 2020
nanobiotix@instinctif.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the forecasts or objectives contained in such forward-looking statements will be confirmed or materialized, which forecasts and objectives are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered by the French Financial Markets Authority (Autorité des marchés financiers) on November 25, 2014 under number R.14-071 (a copy of which is available on www.nanobiotix.com) and to developments in general economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.